EMBRACING
HEALTH

About us

Cevomed acts as a portal paving the way for international pharmaceutical and biotech companies striving to access the MEA healthcare market and it forms as well a link through its distinguished business model in the region between patients and evolutionary health solutions.

read more

EMBRACING
HEALTH

Mission & Vision

We are aiming to be a trusted reference in the MEA region for both patients & partners through our commitment of bringing the highest quality innovative products and health solutions. Cevomed provides the ultimate care for patients and partners need through following cohesively the continuous evolution in health sector.

read more

EMBRACING
HEALTH

Values

Ours values reflect our corporate believes and understanding as they represent the pillars and the corner stones of all our interactions internally and externally.We Take personal accountability for all our actions and results always focusing on finding solutions and achieving results overcoming all the hurdles on the way.

read more

NEUROSCIENCES

In 2007, the World Health Organization estimated that neurological disorders affect up to one billion people worldwide. In fact, neurological diseases make up 11 percent of the world’s disease burden, not including mental health and addiction disorders. Clinical neuroscience is a branch of neuroscience that focuses on the scientific study of fundamental mechanisms that underlie diseases and disorders of the brain and central nervous system. It seeks to develop new ways of diagnosing such disorders and ultimately of developing novel treatments Treated by clinicians including psychiatrists, neurologists, clinical psychologists. Such disorders include Epilepsy, Addiction , Anxiety disorders, bipolar disorder, depression, Migraine, Parkinson's disease…

Zebinix ®
Name: Zebinix® (eslicarbazepine acetate)
Indication:
Zebinix is indicated as monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy and as adjunctive therapy in adults, adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.
Qualitative and Quantitative Composition: Tablets800 mg of eslicarbazepine acetate
Posology:
Adult Patients:
Zebinix may be taken as monotherapy or added to existing anticonvulsant therapy. The recommended starting dose is 400 mg once daily which should be increased to 800 mg once daily after one or two weeks. Based on individual response, the dose may be increased to 1,200 mg once daily Some patients on monotherapy regimen may benefit from a dose of 1,600 mg once daily.
Pediatric Patients:
Children above 6 years of age
The recommended starting dose is 10 mg/kg/day once daily. Dosage should be increased in weekly or bi-weekly increments of 10 mg/kg/day up to 30 mg/kg/day based on individual response. the maximum dose is 1,200 mg once daily.
Children with a body weight of ≥60 kg
Children with a body weight of 60 kg or more should be given the same dose as for adults.

The safety and efficacy of eslicarbazepine acetate in children aged 6 years and below has not yet been established.
Renal impairment
Caution should be exercised in the treatment of patients, adult and children above 6 years of age, with renal impairment and the dose should be adjusted according to creatinine clearance (CLCR) as follows:
- CLCR >60 ml/min: no dose adjustment required.
- CLCR 30-60 ml/min: initial dose of 200 mg (or 5 mg/kg in children above 6 years) once daily or 400 mg (or 10 mg/kg in children above 6 years) every other day for 2 weeks followed by a once daily dose of 400 mg (or 10 mg/kg in children above 6 years). However, based on individual response, the dose may be increased.
- CLCR <30 ml/min: use is not recommended in patients with severe renal impairment due to insufficient data.
ZEBINIX® is the European Union trade name of eslicarbazepine acetate while APTIOM® is the United States trade name for it.
Migretil ®
Qualitative and quantitative composition: Paracetamol 400 mg; caffeine 100 mg; ergotamine tartrate 1 mg; alkaloids Belladonna 0.1 mg; per tablet
Indication: The Treatment of acute attack of migraine and It is not indicated for preventive treatment.
Posology:
Adults: Two tablets, all at once, during the aura or at the beginning of the headache. If necessary, another tablet may be administered after half an hour; this dose may also be repeated after another half an hour.
Adolescents: One tablet during the aura or at onset of headache. If necessary, another tablet may be administered after half an hour. It is not indicated in children under 12 years of age.
Tablets should be taken as soon after the first signs of a migraine attack as possible.
Do not take more than 6 tablets a day or 10-12 tablets a week.

Method of administration
Tablets should be swallowed whole, with some water.
Sedoxil ®
Name: Sedoxil® (Mexazolam)
Indication: Mexazolam is indicated for the management of anxiety disorder associated or not to psychoneurotic conditions.
Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.
Qualitative and Quantitative Composition: tablets 1 mg of Mexazolam.
Posology:
Dosage should be individualised according to the age of patient and severity of symptoms. Adults dosage: on average 1.0 to 3.0 mg per day, preferably divided into 3 doses.
Elderly dosage: do not exceed the dose of 1.5 mg per day.
Children: Sedoxil is not intended for pediatric use
;